The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD

Objective To determine whether the assessment of brain white matter lesion (WML) central veins differentiate patients with primary progressive MS (PPMS) from relapsing-remitting MS (RRMS) and ischemic small vessel disease (SVD) using 3T MRI. Methods In this cross-sectional study, 71 patients with PPMS, RRMS, and SVD were imaged using a T2*-weighted sequence. Two blinded raters identified the total number of WMLs, proportion of WMLs in periventricular, deep white matter (DWM) and juxtacortical regions, and proportion of WMLs with central veins in all patient groups. The proportions were compared between disease groups, including effect sizes. MS or SVD was categorized using a threshold of ≥40% WMLs with central veins as indicative of MS. Interrater and intrarater reproducibility was calculated. Results The mean proportion of WMLs with central veins was 68.4% in PPMS, 74.3% in RRMS, and 4.7% in SVD. The difference in proportions between PPMS and SVD groups was significant (p < 0.0005; effect size: 3.8) but not significant between MS subtypes (p = 0.3; effect size: 0.29). Distribution of WMLs was similar across both MS groups, but despite SVD patients having more DWM lesions than PPMS patients, proportions of WMLs with central veins remained low (2.75% in SVD; 62.5% in PPMS). Interrater and intrarater reproducibility comparing proportions of WMLs with central veins across all patients was 0.86 and 0.90, respectively. Level of agreement between the proportion of WML central veins and established diagnosis was 0.84 and 0.82 for each rater. Conclusions WML central veins could be used to differentiate PPMS from SVD but not between MS subtypes.

[1]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[2]  D. Cottrell,et al.  Primary progressive multiple sclerosis: progress and challenges , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  H. Markus,et al.  Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease , 2016, Brain : a journal of neurology.

[4]  J. MacFall,et al.  Classification of White Matter Lesions on Magnetic Resonance Imaging in Elderly Persons , 2008, Biological Psychiatry.

[5]  Massimo Filippi,et al.  Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies , 2018, Annals of neurology.

[6]  F. Paul,et al.  Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study , 2014, Multiple sclerosis.

[7]  F. Barkhof,et al.  Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a , 2003, Annals of neurology.

[8]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[9]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[10]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[11]  Dennis Bourdette,et al.  “Undiagnosing” multiple sclerosis , 2012, Neurology.

[12]  D. Reich,et al.  Rapid, high-resolution, whole-brain, susceptibility-based MRI of multiple sclerosis , 2014, Multiple sclerosis.

[13]  A. Hofman,et al.  Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study , 1994, Neurology.

[14]  A. Thompson,et al.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.

[15]  Y. Ge,et al.  Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica , 2013, Multiple sclerosis international.

[16]  F. Barkhof,et al.  MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study , 2006, The Lancet Neurology.

[17]  Pascal Sati,et al.  FLAIR*: a combined MR contrast technique for visualizing white matter lesions and parenchymal veins. , 2012, Radiology.

[18]  A. Thompson,et al.  Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis , 2004, Multiple sclerosis.

[19]  Nikos Evangelou,et al.  Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain. , 2013, JAMA neurology.

[20]  S. Ourselin,et al.  Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD , 2018, Neurology.

[21]  F. Barkhof,et al.  Primary and transitional progressive MS , 1999, Neurology.

[22]  J. Simon,et al.  Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients , 2013, Multiple sclerosis.

[23]  D. Reich,et al.  Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: “PT2” , 2016, Multiple sclerosis.

[24]  Roland G. Henry,et al.  The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative , 2016, Nature Reviews Neurology.

[25]  C. Pfueller,et al.  Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis , 2012, Neurology.

[26]  David H. Miller,et al.  MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” , 2006, The Lancet Neurology.

[27]  Nikos Evangelou,et al.  The Central Vein Sign in Multiple Sclerosis Lesions Is Present Irrespective of the T2* Sequence at 3 T , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[28]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[29]  H. Markus,et al.  The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[30]  J. Dawson,et al.  XVIII.–The Histology of Disseminated Sclerosis , 1916, Transactions of the Royal Society of Edinburgh.

[31]  Wei Wen,et al.  The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals , 2004, NeuroImage.

[32]  P S Morgan,et al.  Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions , 2011, Neurology.

[33]  Mike P. Wattjes,et al.  Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla , 2014, European Radiology.

[34]  Christopher Rorden,et al.  The first step for neuroimaging data analysis: DICOM to NIfTI conversion , 2016, Journal of Neuroscience Methods.

[35]  J. Palace.  MAKING THE DIAGNOSIS OF MULTIPLE SCLEROSIS , 2001, Journal of neurology, neurosurgery, and psychiatry.

[36]  I. Deary,et al.  Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities , 2014, Neurology.

[37]  P. Morgan,et al.  Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions , 2016, Multiple sclerosis.

[38]  D P Friedman,et al.  Abnormalities of the deep medullary white matter veins: MR imaging findings. , 1997, AJR. American journal of roentgenology.

[39]  Edmus Coordinating.  Natural history of multiple sclerosis: A unifying concept , 2006 .